Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1689375 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $6.55Day +12.35%Mkt cap $254M1Y +4.1%Off 52W high −60.2%Vol (1Y) 86.2%
Daily closing price, split-adjusted to the current basis; 3y shown of 944 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest5.7% of sh out |
| Days to cover6.3d |
| 13F net flow (QoQ)+1.25% |
| Top-10 13F concentration72.8% |
| Next report (est.)2026-08-06 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$5.7M |
| Earnings (TTM)-$166.1M |
| ROE−39.1% |
| Net margin−565.5% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−36.3% |
| 1Y+4.1% |
| 3Y−62.3% |
| Since incept. (ann.)−21.7% |
Total return through 2026-07-29 · series begins 2022-10-18. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)86.2% |
| Ann. volatility (3Y)74.8% |
| Sharpe (1Y)0.62 |
| Sharpe (3Y)−0.01 |
| Max drawdown (1Y)−64.8% |
| Max drawdown (3Y)−76.7% |
| Beta (3Y vs SPY)0.07 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | 5.1M | $64M | 13.07% | +0.0% |
| 5AM Venture Management, LLC | 4.1M | $51M | 10.45% | +0.0% |
| BlackRock, Inc. | 2.4M | $30M | 6.08% | +9.9% |
| TCG Crossover Management, LLC | 2.3M | $29M | 5.89% | +9.5% |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.3M | $16M | 3.24% | new |
| WELLINGTON MANAGEMENT GROUP LLP | 1.0M | $13M | 2.67% | −1.0% |
| StepStone Group LP | 761,277 | $10M | 1.96% | +0.0% |
| GEODE CAPITAL MANAGEMENT, LLC | 667,347 | $8M | 1.72% | +4.3% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-07 | −$0.95 | — | $875,000 | −95.7% |
| 2025-12-31 | 2026-02-26 | — | — | $1.3M | −96.5% |
| 2025-09-30 | 2025-11-06 | −$1.06 | — | $1.6M | −91.8% |
| 2025-06-30 | 2025-08-06 | −$1.04 | −167.1% | $1.9M | −97.9% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-06 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
